Kathleen Mary Ellen Gallagher, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Immunotherapy, Adoptive | 15 | 2024 | 1505 | 1.390 |
Why?
|
Mumps | 8 | 2014 | 71 | 1.370 |
Why?
|
Disease Outbreaks | 13 | 2023 | 1763 | 0.940 |
Why?
|
B-Cell Maturation Antigen | 2 | 2024 | 149 | 0.880 |
Why?
|
Measles | 5 | 2022 | 181 | 0.830 |
Why?
|
Population Surveillance | 13 | 2017 | 2601 | 0.830 |
Why?
|
Measles-Mumps-Rubella Vaccine | 6 | 2013 | 71 | 0.800 |
Why?
|
Behavioral Risk Factor Surveillance System | 4 | 2007 | 211 | 0.630 |
Why?
|
Multiple Myeloma | 4 | 2024 | 5193 | 0.620 |
Why?
|
Flow Cytometry | 5 | 2024 | 5893 | 0.580 |
Why?
|
Ethiopia | 8 | 2023 | 481 | 0.550 |
Why?
|
Measles virus | 2 | 2016 | 67 | 0.540 |
Why?
|
Mumps Vaccine | 2 | 2014 | 16 | 0.540 |
Why?
|
Public Health Administration | 4 | 2007 | 242 | 0.530 |
Why?
|
Vaccination | 9 | 2022 | 3433 | 0.530 |
Why?
|
Sentinel Surveillance | 2 | 2018 | 292 | 0.520 |
Why?
|
Immunization Programs | 5 | 2017 | 267 | 0.520 |
Why?
|
Risk-Taking | 5 | 2007 | 1041 | 0.500 |
Why?
|
Laboratories | 2 | 2021 | 463 | 0.490 |
Why?
|
Homosexuality, Male | 7 | 2007 | 1343 | 0.490 |
Why?
|
Immunization | 2 | 2017 | 1220 | 0.440 |
Why?
|
Immunization, Secondary | 2 | 2012 | 371 | 0.430 |
Why?
|
CD4-Positive T-Lymphocytes | 7 | 2012 | 4403 | 0.400 |
Why?
|
Health Behavior | 3 | 2017 | 2649 | 0.400 |
Why?
|
Jews | 1 | 2012 | 358 | 0.360 |
Why?
|
Drug Resistance, Bacterial | 1 | 2018 | 1061 | 0.350 |
Why?
|
Receptors, Antigen, T-Cell | 4 | 2024 | 2564 | 0.330 |
Why?
|
Interferon-alpha | 2 | 2012 | 909 | 0.320 |
Why?
|
T-Lymphocytes | 13 | 2024 | 10269 | 0.310 |
Why?
|
Epitopes, T-Lymphocyte | 4 | 2021 | 822 | 0.310 |
Why?
|
Vaccines | 1 | 2017 | 845 | 0.310 |
Why?
|
HLA-DR1 Antigen | 1 | 2007 | 11 | 0.290 |
Why?
|
Urban Health | 2 | 2007 | 535 | 0.290 |
Why?
|
Immunologic Memory | 4 | 2010 | 1371 | 0.280 |
Why?
|
Measles Vaccine | 2 | 2017 | 79 | 0.270 |
Why?
|
HLA-DR Antigens | 2 | 2008 | 606 | 0.270 |
Why?
|
Human papillomavirus 18 | 1 | 2007 | 126 | 0.270 |
Why?
|
New York | 6 | 2014 | 881 | 0.260 |
Why?
|
Human papillomavirus 16 | 1 | 2007 | 269 | 0.240 |
Why?
|
Poliovirus Vaccines | 2 | 2017 | 13 | 0.240 |
Why?
|
Hepatitis B | 2 | 2009 | 707 | 0.230 |
Why?
|
Poliomyelitis | 2 | 2017 | 92 | 0.230 |
Why?
|
Daunorubicin | 1 | 2023 | 157 | 0.220 |
Why?
|
Bronchiolitis Obliterans | 1 | 2025 | 220 | 0.210 |
Why?
|
Hepatitis C | 3 | 2009 | 1594 | 0.210 |
Why?
|
Central Nervous System Neoplasms | 2 | 2022 | 928 | 0.200 |
Why?
|
Leukemia, Myeloid, Acute | 3 | 2023 | 3623 | 0.190 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 2 | 2022 | 1427 | 0.190 |
Why?
|
Lymphoma | 2 | 2022 | 1907 | 0.190 |
Why?
|
Hematologic Neoplasms | 3 | 2024 | 1905 | 0.190 |
Why?
|
HIV Infections | 8 | 2010 | 17492 | 0.190 |
Why?
|
Influenza Vaccines | 2 | 2012 | 781 | 0.180 |
Why?
|
Antineoplastic Agents | 1 | 2023 | 13709 | 0.180 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 1 | 2022 | 299 | 0.170 |
Why?
|
Influenza, Human | 2 | 2012 | 1540 | 0.170 |
Why?
|
Communicable Diseases | 2 | 2022 | 875 | 0.170 |
Why?
|
Tumor Necrosis Factor Ligand Superfamily Member 13 | 1 | 2019 | 40 | 0.170 |
Why?
|
Humans | 70 | 2025 | 768369 | 0.170 |
Why?
|
Adolescent | 23 | 2019 | 89163 | 0.170 |
Why?
|
Nitriles | 1 | 2025 | 984 | 0.170 |
Why?
|
Antibodies, Viral | 4 | 2022 | 3210 | 0.160 |
Why?
|
Sexual Behavior | 2 | 2006 | 2200 | 0.160 |
Why?
|
Anti-Bacterial Agents | 1 | 2018 | 7467 | 0.160 |
Why?
|
CD8-Positive T-Lymphocytes | 3 | 2024 | 4613 | 0.160 |
Why?
|
Age Distribution | 4 | 2017 | 2881 | 0.160 |
Why?
|
Mass Screening | 3 | 2009 | 5455 | 0.150 |
Why?
|
Open Reading Frames | 1 | 2021 | 813 | 0.150 |
Why?
|
Neurotoxicity Syndromes | 1 | 2022 | 303 | 0.150 |
Why?
|
Disease Notification | 2 | 2013 | 95 | 0.150 |
Why?
|
Hepatitis C, Chronic | 3 | 2012 | 1031 | 0.150 |
Why?
|
Security Measures | 1 | 2018 | 83 | 0.140 |
Why?
|
Infant | 12 | 2017 | 36496 | 0.140 |
Why?
|
Epidemics | 1 | 2023 | 517 | 0.140 |
Why?
|
Antigens, Neoplasm | 3 | 2024 | 2003 | 0.140 |
Why?
|
Cholera | 1 | 2023 | 753 | 0.140 |
Why?
|
Pyrimidines | 2 | 2025 | 3050 | 0.130 |
Why?
|
Specimen Handling | 1 | 2021 | 709 | 0.130 |
Why?
|
Adult | 30 | 2025 | 223528 | 0.130 |
Why?
|
Contact Tracing | 2 | 2022 | 275 | 0.120 |
Why?
|
Piperazines | 1 | 2006 | 2546 | 0.120 |
Why?
|
Capacity Building | 1 | 2018 | 265 | 0.120 |
Why?
|
Antigens, CD19 | 3 | 2022 | 437 | 0.120 |
Why?
|
Rubella | 2 | 2011 | 55 | 0.120 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2021 | 1355 | 0.120 |
Why?
|
Public Health | 3 | 2022 | 2693 | 0.120 |
Why?
|
Male | 36 | 2025 | 364761 | 0.120 |
Why?
|
Child, Preschool | 12 | 2023 | 42620 | 0.120 |
Why?
|
Pyrazoles | 1 | 2025 | 2024 | 0.110 |
Why?
|
Hepatitis A Vaccines | 2 | 2011 | 26 | 0.110 |
Why?
|
Young Adult | 12 | 2019 | 60038 | 0.110 |
Why?
|
Religion | 1 | 2017 | 377 | 0.110 |
Why?
|
Hepatitis A | 2 | 2011 | 127 | 0.110 |
Why?
|
Epitopes | 2 | 2012 | 2523 | 0.110 |
Why?
|
Biological Products | 1 | 2022 | 937 | 0.110 |
Why?
|
Syphilis | 2 | 2005 | 242 | 0.100 |
Why?
|
Orchitis | 1 | 2012 | 36 | 0.100 |
Why?
|
Middle Aged | 22 | 2025 | 223406 | 0.100 |
Why?
|
New Jersey | 1 | 2012 | 295 | 0.100 |
Why?
|
Peptides | 3 | 2021 | 4368 | 0.100 |
Why?
|
Hepatitis A Antibodies | 1 | 2011 | 19 | 0.100 |
Why?
|
Female | 30 | 2025 | 396926 | 0.100 |
Why?
|
Aviation | 1 | 2011 | 49 | 0.100 |
Why?
|
Neoplastic Stem Cells | 1 | 2019 | 1357 | 0.100 |
Why?
|
Child | 15 | 2017 | 80856 | 0.090 |
Why?
|
Hematopoietic Stem Cell Transplantation | 3 | 2025 | 5708 | 0.090 |
Why?
|
Poliovirus | 1 | 2012 | 106 | 0.090 |
Why?
|
Immunization Schedule | 1 | 2012 | 227 | 0.090 |
Why?
|
Health Personnel | 3 | 2021 | 3384 | 0.090 |
Why?
|
United States | 19 | 2022 | 73120 | 0.090 |
Why?
|
Proteome | 1 | 2021 | 1881 | 0.090 |
Why?
|
Mumps virus | 1 | 2010 | 23 | 0.090 |
Why?
|
Public Sector | 1 | 2012 | 265 | 0.090 |
Why?
|
Orthomyxoviridae | 1 | 2012 | 148 | 0.090 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2022 | 1644 | 0.090 |
Why?
|
Health Education | 1 | 2017 | 1059 | 0.090 |
Why?
|
Enzyme-Linked Immunospot Assay | 1 | 2010 | 124 | 0.090 |
Why?
|
Sexually Transmitted Diseases, Viral | 1 | 2010 | 39 | 0.090 |
Why?
|
Sex Distribution | 2 | 2012 | 2286 | 0.080 |
Why?
|
Tuberculin | 1 | 2009 | 64 | 0.080 |
Why?
|
Cost of Illness | 2 | 2017 | 1960 | 0.080 |
Why?
|
Leukocytes, Mononuclear | 2 | 2022 | 1852 | 0.080 |
Why?
|
Urban Population | 1 | 2017 | 2047 | 0.080 |
Why?
|
Tetanus Toxoid | 1 | 2009 | 189 | 0.080 |
Why?
|
Cambodia | 1 | 2009 | 185 | 0.080 |
Why?
|
Glioblastoma | 1 | 2024 | 3524 | 0.080 |
Why?
|
Washington | 1 | 2009 | 314 | 0.080 |
Why?
|
AIDS Serodiagnosis | 1 | 2010 | 220 | 0.080 |
Why?
|
Acquired Immunodeficiency Syndrome | 4 | 2005 | 2201 | 0.080 |
Why?
|
Peritoneal Dialysis | 1 | 2009 | 160 | 0.080 |
Why?
|
Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2009 | 161 | 0.080 |
Why?
|
HLA-A2 Antigen | 1 | 2008 | 209 | 0.080 |
Why?
|
Injections, Subcutaneous | 1 | 2009 | 681 | 0.070 |
Why?
|
Antiretroviral Therapy, Highly Active | 2 | 2007 | 1898 | 0.070 |
Why?
|
Hepatitis, Viral, Human | 1 | 2008 | 141 | 0.070 |
Why?
|
Nucleic Acid Amplification Techniques | 1 | 2010 | 333 | 0.070 |
Why?
|
Peritonitis | 1 | 2009 | 368 | 0.070 |
Why?
|
Disease Transmission, Infectious | 1 | 2012 | 562 | 0.070 |
Why?
|
Incidence | 6 | 2017 | 21552 | 0.070 |
Why?
|
Lymphocyte Activation | 3 | 2019 | 5490 | 0.070 |
Why?
|
Aged | 14 | 2025 | 171514 | 0.070 |
Why?
|
Immunoassay | 1 | 2010 | 746 | 0.070 |
Why?
|
Cognition | 1 | 2023 | 7062 | 0.060 |
Why?
|
Travel | 1 | 2011 | 800 | 0.060 |
Why?
|
Hepacivirus | 1 | 2012 | 1342 | 0.060 |
Why?
|
Models, Theoretical | 1 | 2017 | 3590 | 0.060 |
Why?
|
Antigens, CD7 | 1 | 2024 | 29 | 0.060 |
Why?
|
California | 1 | 2009 | 1444 | 0.060 |
Why?
|
Unsafe Sex | 1 | 2007 | 239 | 0.060 |
Why?
|
Caregivers | 1 | 2017 | 2302 | 0.060 |
Why?
|
Geography | 1 | 2007 | 654 | 0.060 |
Why?
|
Infant, Newborn | 3 | 2016 | 26394 | 0.060 |
Why?
|
Schools | 1 | 2012 | 1496 | 0.060 |
Why?
|
Substance Abuse, Intravenous | 2 | 2007 | 530 | 0.050 |
Why?
|
Health Care Costs | 2 | 2014 | 3266 | 0.050 |
Why?
|
Papillomavirus Vaccines | 2 | 2007 | 497 | 0.050 |
Why?
|
Sulfones | 1 | 2006 | 448 | 0.050 |
Why?
|
Guam | 2 | 2013 | 31 | 0.050 |
Why?
|
Oncogene Proteins, Viral | 1 | 2004 | 342 | 0.050 |
Why?
|
Aminoglycosides | 1 | 2023 | 161 | 0.050 |
Why?
|
HIV Antibodies | 1 | 2010 | 1335 | 0.050 |
Why?
|
Sanitation | 1 | 2023 | 83 | 0.050 |
Why?
|
Purines | 1 | 2006 | 614 | 0.050 |
Why?
|
Membrane Proteins | 1 | 2019 | 7895 | 0.050 |
Why?
|
Emigrants and Immigrants | 1 | 2009 | 548 | 0.050 |
Why?
|
Cells, Cultured | 2 | 2009 | 19035 | 0.050 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2017 | 4049 | 0.050 |
Why?
|
Rubella virus | 2 | 2011 | 11 | 0.050 |
Why?
|
Immunoenzyme Techniques | 1 | 2004 | 1706 | 0.050 |
Why?
|
Cytarabine | 1 | 2023 | 697 | 0.050 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2005 | 664 | 0.050 |
Why?
|
Genotype | 1 | 2016 | 13045 | 0.050 |
Why?
|
Prospective Studies | 3 | 2025 | 54913 | 0.050 |
Why?
|
Thiazoles | 1 | 2008 | 1541 | 0.050 |
Why?
|
Program Evaluation | 1 | 2009 | 2508 | 0.050 |
Why?
|
Transgenes | 1 | 2024 | 1015 | 0.040 |
Why?
|
Pneumococcal Infections | 1 | 2005 | 529 | 0.040 |
Why?
|
Reference Values | 1 | 2007 | 4941 | 0.040 |
Why?
|
Treatment Outcome | 5 | 2025 | 65408 | 0.040 |
Why?
|
T-Cell Antigen Receptor Specificity | 1 | 2019 | 87 | 0.040 |
Why?
|
Logistic Models | 2 | 2017 | 13323 | 0.040 |
Why?
|
Sexually Transmitted Diseases | 1 | 2005 | 665 | 0.040 |
Why?
|
Macrophage Activation | 1 | 2022 | 556 | 0.040 |
Why?
|
Age Factors | 2 | 2012 | 18477 | 0.040 |
Why?
|
Cytokines | 3 | 2022 | 7440 | 0.040 |
Why?
|
Administration, Oral | 1 | 2006 | 4040 | 0.040 |
Why?
|
Attitude to Health | 1 | 2007 | 2030 | 0.040 |
Why?
|
Environmental Exposure | 1 | 2012 | 4533 | 0.040 |
Why?
|
B-Lymphocytes | 1 | 2010 | 4779 | 0.040 |
Why?
|
Kidney Failure, Chronic | 1 | 2009 | 2489 | 0.030 |
Why?
|
CD4 Lymphocyte Count | 1 | 2003 | 2589 | 0.030 |
Why?
|
Transplantation, Homologous | 1 | 2025 | 4834 | 0.030 |
Why?
|
Cross-Sectional Studies | 1 | 2017 | 26348 | 0.030 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2019 | 1352 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2007 | 5308 | 0.030 |
Why?
|
Antigen Presentation | 1 | 2021 | 1247 | 0.030 |
Why?
|
Reproducibility of Results | 3 | 2021 | 20232 | 0.030 |
Why?
|
Prevalence | 3 | 2010 | 15879 | 0.030 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2024 | 9425 | 0.030 |
Why?
|
Immunophenotyping | 1 | 2019 | 1868 | 0.030 |
Why?
|
Patient Selection | 1 | 2007 | 4266 | 0.030 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2008 | 3105 | 0.030 |
Why?
|
Community-Institutional Relations | 2 | 2005 | 208 | 0.030 |
Why?
|
Antigens, CD | 1 | 2024 | 4022 | 0.030 |
Why?
|
Cell Proliferation | 1 | 2009 | 10490 | 0.030 |
Why?
|
Kinetics | 1 | 2021 | 6347 | 0.030 |
Why?
|
Amino Acid Sequence | 2 | 2021 | 13447 | 0.030 |
Why?
|
Interferon-gamma | 1 | 2022 | 3164 | 0.030 |
Why?
|
Health Promotion | 1 | 2005 | 2215 | 0.030 |
Why?
|
Risk Factors | 5 | 2023 | 74915 | 0.030 |
Why?
|
Neoplasms | 1 | 2022 | 22389 | 0.030 |
Why?
|
Natural Cytotoxicity Triggering Receptor 1 | 1 | 2012 | 29 | 0.030 |
Why?
|
Papillomavirus Infections | 1 | 2004 | 1637 | 0.030 |
Why?
|
Massachusetts | 2 | 2003 | 8905 | 0.030 |
Why?
|
Rubella Vaccine | 1 | 2011 | 23 | 0.030 |
Why?
|
Mice | 4 | 2024 | 82051 | 0.020 |
Why?
|
Graft vs Host Disease | 1 | 2025 | 3042 | 0.020 |
Why?
|
Protein Kinase Inhibitors | 1 | 2008 | 5709 | 0.020 |
Why?
|
Antibodies, Neutralizing | 1 | 2022 | 2005 | 0.020 |
Why?
|
Recurrence | 1 | 2024 | 8510 | 0.020 |
Why?
|
Crowding | 1 | 2013 | 144 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2021 | 4294 | 0.020 |
Why?
|
Cell Growth Processes | 1 | 2012 | 383 | 0.020 |
Why?
|
Biotinylation | 1 | 2012 | 184 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2019 | 3619 | 0.020 |
Why?
|
Surface Plasmon Resonance | 1 | 2012 | 270 | 0.020 |
Why?
|
Viral Load | 2 | 2012 | 3374 | 0.020 |
Why?
|
Antibody-Producing Cells | 1 | 2010 | 140 | 0.020 |
Why?
|
Molecular Conformation | 1 | 2012 | 542 | 0.020 |
Why?
|
Mexican Americans | 1 | 2011 | 164 | 0.020 |
Why?
|
Alleles | 1 | 2021 | 6880 | 0.020 |
Why?
|
Seroepidemiologic Studies | 1 | 2011 | 406 | 0.020 |
Why?
|
Time Factors | 2 | 2012 | 40271 | 0.020 |
Why?
|
Alanine Transaminase | 1 | 2012 | 605 | 0.020 |
Why?
|
Los Angeles | 1 | 2010 | 245 | 0.020 |
Why?
|
Peritoneal Cavity | 1 | 2009 | 135 | 0.020 |
Why?
|
Colorectal Neoplasms | 1 | 2009 | 6979 | 0.020 |
Why?
|
U937 Cells | 1 | 2009 | 260 | 0.020 |
Why?
|
Florida | 1 | 2010 | 430 | 0.020 |
Why?
|
Hepatitis C Antigens | 1 | 2008 | 34 | 0.020 |
Why?
|
Reagent Kits, Diagnostic | 1 | 2010 | 239 | 0.020 |
Why?
|
Risk Assessment | 2 | 2007 | 24310 | 0.020 |
Why?
|
Hepatitis C Antibodies | 1 | 2008 | 151 | 0.020 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2012 | 1438 | 0.020 |
Why?
|
DNA-Binding Proteins | 1 | 2004 | 9623 | 0.020 |
Why?
|
Protein Binding | 1 | 2019 | 9376 | 0.020 |
Why?
|
Animals | 4 | 2024 | 169424 | 0.020 |
Why?
|
Hepatitis B Vaccines | 1 | 2008 | 177 | 0.020 |
Why?
|
Anti-HIV Agents | 1 | 2003 | 4563 | 0.020 |
Why?
|
Interleukin-10 | 1 | 2012 | 1184 | 0.020 |
Why?
|
Gene Expression | 1 | 2019 | 7605 | 0.020 |
Why?
|
Treatment Failure | 1 | 2013 | 2655 | 0.020 |
Why?
|
Models, Immunological | 1 | 2008 | 516 | 0.020 |
Why?
|
Immunity | 1 | 2012 | 1002 | 0.020 |
Why?
|
Puerto Rico | 1 | 2007 | 381 | 0.020 |
Why?
|
Poisson Distribution | 1 | 2007 | 509 | 0.020 |
Why?
|
Sampling Studies | 1 | 2007 | 617 | 0.020 |
Why?
|
Guidelines as Topic | 1 | 2011 | 1395 | 0.020 |
Why?
|
Temperature | 1 | 2012 | 2237 | 0.020 |
Why?
|
Case-Control Studies | 1 | 2023 | 22286 | 0.020 |
Why?
|
India | 1 | 2011 | 2323 | 0.020 |
Why?
|
Viremia | 1 | 2008 | 715 | 0.010 |
Why?
|
Protein Structure, Tertiary | 1 | 2012 | 3790 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2019 | 12561 | 0.010 |
Why?
|
Developing Countries | 1 | 2017 | 2901 | 0.010 |
Why?
|
Staining and Labeling | 1 | 2008 | 1083 | 0.010 |
Why?
|
Nutrition Surveys | 1 | 2011 | 1734 | 0.010 |
Why?
|
Parents | 1 | 2017 | 3596 | 0.010 |
Why?
|
Killer Cells, Natural | 1 | 2012 | 2207 | 0.010 |
Why?
|
New York City | 1 | 2005 | 738 | 0.010 |
Why?
|
Cities | 1 | 2005 | 545 | 0.010 |
Why?
|
Communication | 1 | 2017 | 3910 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 11844 | 0.010 |
Why?
|
Students | 1 | 2013 | 1751 | 0.010 |
Why?
|
Pandemics | 1 | 2022 | 8751 | 0.010 |
Why?
|
Vulvar Neoplasms | 1 | 2004 | 267 | 0.010 |
Why?
|
Vaccines, Synthetic | 1 | 2004 | 622 | 0.010 |
Why?
|
Retrospective Studies | 4 | 2019 | 81835 | 0.010 |
Why?
|
Models, Genetic | 1 | 2012 | 3442 | 0.010 |
Why?
|
Models, Molecular | 1 | 2012 | 5441 | 0.010 |
Why?
|
Aged, 80 and over | 3 | 2012 | 59679 | 0.010 |
Why?
|
Family | 1 | 2012 | 3208 | 0.010 |
Why?
|
Cohort Studies | 3 | 2012 | 41782 | 0.010 |
Why?
|
Uterine Cervical Dysplasia | 1 | 2004 | 387 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 3813 | 0.010 |
Why?
|
Health Services | 1 | 2005 | 756 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2019 | 18390 | 0.010 |
Why?
|
Up-Regulation | 1 | 2009 | 4132 | 0.010 |
Why?
|
Risk | 1 | 2012 | 9642 | 0.010 |
Why?
|
Viral Vaccines | 1 | 2004 | 595 | 0.010 |
Why?
|
Program Development | 1 | 2005 | 1296 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2013 | 7863 | 0.010 |
Why?
|
Prognosis | 1 | 2019 | 30031 | 0.010 |
Why?
|
Papillomaviridae | 1 | 2004 | 1135 | 0.010 |
Why?
|
Acute Disease | 1 | 2008 | 7245 | 0.010 |
Why?
|
Patient Compliance | 1 | 2007 | 2696 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2008 | 9558 | 0.010 |
Why?
|
Models, Biological | 1 | 2012 | 9505 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2010 | 14725 | 0.010 |
Why?
|
Medical Records | 1 | 2000 | 1413 | 0.010 |
Why?
|
Pneumonia, Pneumocystis | 1 | 1995 | 242 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2009 | 8636 | 0.010 |
Why?
|
Candidiasis | 1 | 1995 | 367 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2004 | 17637 | 0.010 |
Why?
|
Health Services Accessibility | 1 | 2005 | 5508 | 0.000 |
Why?
|
Medicaid | 1 | 2000 | 2843 | 0.000 |
Why?
|
Survivors | 1 | 1995 | 2379 | 0.000 |
Why?
|
Registries | 1 | 2000 | 8372 | 0.000 |
Why?
|
Tuberculosis | 1 | 1995 | 2029 | 0.000 |
Why?
|
Boston | 1 | 1995 | 9359 | 0.000 |
Why?
|